Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-983. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaToll-like receptor 9 agonistPF-3512676Receptor 9 agonistT-cell lymphomaSézary syndromeMycosis fungoidesIVa cutaneous T cell lymphomaRefractory cutaneous T-cell lymphomaPhase I dose-escalation studyI dose-escalation studyClass of lymphomasIndex Lesion SeverityClinical response rateCommon adverse eventsPhysician global assessmentPrimary end pointDose-escalation studyPhase I trialWeekly subcutaneous injectionsLimited therapeutic optionsTreatment of patientsEnd of studyStage IBAdverse events